Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
11/08/2023
Locations: Research Site, White Marsh, Maryland
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
11/08/2023
Locations: Research Site, Baltimore, Maryland
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Motivational Interviewing and Air Cleaners for Smokers With COPD (MOVE COPD)
Recruiting
COPD is characterized by lung injury and inflammation caused by noxious particles and gases, including those emanating from cigarette smoke and air pollution. Despite the clear detrimental impact of poor air quality on respiratory outcomes, regardless of smoking status, to investigators' knowledge, there are no studied environmental interventions targeting indoor air quality to improve respiratory health of smokers, thus ignoring a potential target for harm reduction. Investigators propose a ran... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
06/14/2023
Locations: Johns Hopkins Bayview Campus, Baltimore, Maryland
Conditions: COPD, Chronic Obstructive Pulmonary Disease
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 600 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: To use CT scan imaging to identify which smokers will develop COPD. To identify biomarkers predictive of smokers that will develop COPD. To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related que... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
04/12/2023
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: COPD, Early-Onset
OMEGA - Dietary Intervention - COPD Trial
Recruiting
A randomized controlled trial of a food delivery dietary intervention targeting increased omega-3 intake to determine whether dietary modifications can improve Chronic Obstructive Pulmonary Disease (COPD) outcomes and attenuate the adverse effects of particulate matter on respiratory health. Investigators believe that study results will comprehensively address the impact of an evidence-based nutrition intervention on COPD health and provide a framework for dietary intervention within other chro... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
03/16/2023
Locations: Johns Hopkins Bayview Campus, Baltimore, Maryland
Conditions: COPD, Chronic Obstructive Pulmonary Disease